4.7 Article

Streamlining clinical research: an ESMO awareness call to improve sponsoring and monitoring of clinical trials

Journal

ANNALS OF ONCOLOGY
Volume 34, Issue 1, Pages 70-77

Publisher

ELSEVIER
DOI: 10.1016/j.annonc.2022.09.162

Keywords

clinical trials; Good Clinical Practice; Declaration of Helsinki; clinical trial sponsoring; clinical trial monitoring

Categories

Ask authors/readers for more resources

In recent years, the burden of bureaucracy in clinical research has significantly increased, negatively impacting investigators and clinical research teams. While compliance with regulations and guidelines is important, the overinterpretation and substitution by sponsors and CROs have increased administrative burden. A survey among 940 investigators confirmed excessive administrative burden and bureaucracy as obstacles to clinical research.
Background: During recent years, the burden of bureaucracy in clinical research has increased dramatically, adversely impacting the activity of investigators and clinical research teams. Although compliance with the Declaration of Helsinki, the guidelines for Good Clinical Practice (GCP), and other applicable regulations remains unquestionable, their overinterpretation and substitution by the internal operating procedures of sponsors and Contract Research Organizations (CROs) have increased the administrative burden. A survey conducted by the European Society for Medical Oncology (ESMO) Clinical Research Observatory (ECRO) among 940 investigators confirmed that they considered that the administrative burden in clinical research is excessive; that administrative procedures could be reduced without affecting the safety and the rights of the patients and the quality of the data; and that bureaucracy represents an obstacle for clinical research.Methods: A panel of physicians with extensive experience in clinical research, composed by members of the ECRO and the ESMO Scientific Medical and Public Policy divisions, analyzed clinical trial procedures related to administrative workflow, pharmacovigilance, and medical care.Results: The panel identified situations that generate debate between investigators and sponsors/CROs and selected real clinical scenarios that exemplify such situations. The panel discussed and proposed specific recommendations for those situations, based on GCP.Conclusions: This initiative aspires to streamline clinical research procedures and to become a platform for discussion among all clinical trial stakeholders, with the aim of promoting the sustainability of clinical research and the care of cancer patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available